News | July 28, 2025
GSK forges $12 billion alliance with Hengrui Pharma
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
The company received one observation in the Form-483
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
This marks the fourth acquisition by Corona Remedies from multinational corporations
Subscribe To Our Newsletter & Stay Updated
